Sang-Eun Lee, Soomin Park, Rian Kang, Taehoon Lee, Won Jong Yu, Sunghoe Chang, Jong-Chan Park
{"title":"阿尔茨海默病中海马tau诱导的GRIN3A缺乏症","authors":"Sang-Eun Lee, Soomin Park, Rian Kang, Taehoon Lee, Won Jong Yu, Sunghoe Chang, Jong-Chan Park","doi":"10.1002/2211-5463.13904","DOIUrl":null,"url":null,"abstract":"<p>Alzheimer's disease (AD) is characterized by significant alterations in hippocampal function and structure, but the molecular mechanisms underlying the hippocampal region remain elusive. We integrated multiple transcriptome datasets including human or rat hippocampus (GSE173955, GSE129051, GSE84422) to identify candidate genes. Subsequent analyses including gene ontology analysis and protein–protein interaction mapping were performed to identify key genes and pathways. We found that glutamate ionotropic receptor NMDA-type subunit 3A (<i>GRIN3A</i>) and glutamate metabotropic receptor 8 (<i>GRM8</i>), which are related to the glutamatergic system, were the top two annotated genes and directly related to <i>MAPT</i>, which encodes a tau protein. Since there is no direct evidence of interaction between tauopathy and these genes in AD, further transcriptomic data (GSE125957, GSE56772) from tau transgenic mice and experimental validations through primary rat hippocampal neurons and induced pluripotent stem cell (iPSC)-derived brain organoids were performed. Interestingly, we identified that decreased NR3A (encoded by <i>GRIN3A</i>) and mGluR8 (encoded by <i>GRM8</i>) are correlated with tauopathy and loss of postsynaptic function in AD. Taken together, our results identified a novel tauopathy biomarker <i>GRIN3A</i> in AD. Furthermore, our findings suggest that an integrated approach combining public databases and diverse experimental validations can contribute to the advancement of precision medicine therapies.</p>","PeriodicalId":12187,"journal":{"name":"FEBS Open Bio","volume":"14 12","pages":"2059-2071"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/2211-5463.13904","citationCount":"0","resultStr":"{\"title\":\"Hippocampal tau-induced GRIN3A deficiency in Alzheimer's disease\",\"authors\":\"Sang-Eun Lee, Soomin Park, Rian Kang, Taehoon Lee, Won Jong Yu, Sunghoe Chang, Jong-Chan Park\",\"doi\":\"10.1002/2211-5463.13904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Alzheimer's disease (AD) is characterized by significant alterations in hippocampal function and structure, but the molecular mechanisms underlying the hippocampal region remain elusive. We integrated multiple transcriptome datasets including human or rat hippocampus (GSE173955, GSE129051, GSE84422) to identify candidate genes. Subsequent analyses including gene ontology analysis and protein–protein interaction mapping were performed to identify key genes and pathways. We found that glutamate ionotropic receptor NMDA-type subunit 3A (<i>GRIN3A</i>) and glutamate metabotropic receptor 8 (<i>GRM8</i>), which are related to the glutamatergic system, were the top two annotated genes and directly related to <i>MAPT</i>, which encodes a tau protein. Since there is no direct evidence of interaction between tauopathy and these genes in AD, further transcriptomic data (GSE125957, GSE56772) from tau transgenic mice and experimental validations through primary rat hippocampal neurons and induced pluripotent stem cell (iPSC)-derived brain organoids were performed. Interestingly, we identified that decreased NR3A (encoded by <i>GRIN3A</i>) and mGluR8 (encoded by <i>GRM8</i>) are correlated with tauopathy and loss of postsynaptic function in AD. Taken together, our results identified a novel tauopathy biomarker <i>GRIN3A</i> in AD. Furthermore, our findings suggest that an integrated approach combining public databases and diverse experimental validations can contribute to the advancement of precision medicine therapies.</p>\",\"PeriodicalId\":12187,\"journal\":{\"name\":\"FEBS Open Bio\",\"volume\":\"14 12\",\"pages\":\"2059-2071\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/2211-5463.13904\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FEBS Open Bio\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/2211-5463.13904\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FEBS Open Bio","FirstCategoryId":"99","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/2211-5463.13904","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
阿尔茨海默病(AD)的特征是海马功能和结构的显著改变,但海马区的分子机制仍然难以捉摸。我们整合了包括人类或大鼠海马在内的多个转录组数据集(GSE173955、GSE129051、GSE84422),以确定候选基因。随后进行的分析包括基因本体分析和蛋白-蛋白相互作用图谱,以确定关键基因和通路。我们发现,与谷氨酸能系统有关的谷氨酸离子型受体 NMDA 型亚基 3A(GRIN3A)和谷氨酸代谢型受体 8(GRM8)是前两个注释基因,并与编码 tau 蛋白的 MAPT 直接相关。由于没有直接证据表明tauopathy与这些基因在AD中存在相互作用,我们进一步收集了tau转基因小鼠的转录组数据(GSE125957、GSE56772),并通过原代大鼠海马神经元和诱导多能干细胞(iPSC)衍生的脑器官组织进行了实验验证。有趣的是,我们发现NR3A(由GRIN3A编码)和mGluR8(由GRM8编码)的减少与突触病和AD突触后功能丧失相关。综上所述,我们的研究结果发现了一种新型牛磺酸病生物标志物 GRIN3A。此外,我们的研究结果表明,结合公共数据库和各种实验验证的综合方法有助于促进精准医学疗法的发展。
Hippocampal tau-induced GRIN3A deficiency in Alzheimer's disease
Alzheimer's disease (AD) is characterized by significant alterations in hippocampal function and structure, but the molecular mechanisms underlying the hippocampal region remain elusive. We integrated multiple transcriptome datasets including human or rat hippocampus (GSE173955, GSE129051, GSE84422) to identify candidate genes. Subsequent analyses including gene ontology analysis and protein–protein interaction mapping were performed to identify key genes and pathways. We found that glutamate ionotropic receptor NMDA-type subunit 3A (GRIN3A) and glutamate metabotropic receptor 8 (GRM8), which are related to the glutamatergic system, were the top two annotated genes and directly related to MAPT, which encodes a tau protein. Since there is no direct evidence of interaction between tauopathy and these genes in AD, further transcriptomic data (GSE125957, GSE56772) from tau transgenic mice and experimental validations through primary rat hippocampal neurons and induced pluripotent stem cell (iPSC)-derived brain organoids were performed. Interestingly, we identified that decreased NR3A (encoded by GRIN3A) and mGluR8 (encoded by GRM8) are correlated with tauopathy and loss of postsynaptic function in AD. Taken together, our results identified a novel tauopathy biomarker GRIN3A in AD. Furthermore, our findings suggest that an integrated approach combining public databases and diverse experimental validations can contribute to the advancement of precision medicine therapies.
期刊介绍:
FEBS Open Bio is an online-only open access journal for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The journal''s peer review process focuses on the technical soundness of papers, leaving the assessment of their impact and importance to the scientific community.
FEBS Open Bio is owned by the Federation of European Biochemical Societies (FEBS), a not-for-profit organization, and is published on behalf of FEBS by FEBS Press and Wiley. Any income from the journal will be used to support scientists through fellowships, courses, travel grants, prizes and other FEBS initiatives.